{"nctId":"NCT01503021","briefTitle":"Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis","startDateStruct":{"date":"2011-11"},"conditions":["End Stage Renal Disease","Chronic Kidney Disease"],"count":718,"armGroups":[{"label":"SFP/Placebo","type":"OTHER","interventionNames":["Drug: SFP","Other: Placebo"]},{"label":"Placebo/SFP","type":"OTHER","interventionNames":["Drug: SFP","Other: Placebo"]}],"interventions":[{"name":"SFP","otherNames":["Soluble ferric pyrophosphate"]},{"name":"Placebo","otherNames":["Standard liquid bicarbonate concentrate"]}],"eligibilityModule":{"eligibilityCriteria":"Parent Study, Double Blinded, Crossover:\n\nKey Inclusion Criteria:\n\n1. Adult ≥ 18 years of age.\n2. Has chronic kidney disease (CKD) receiving maintenance hemodialysis (HD) (CKD-HD subjects) and regularly undergoing 2 or more dialysis sessions per week.\n3. Stable pre-dialysis Hgb ≥ 9.0 to ≤ 12.5 g/dL.\n4. Stable pre-dialysis TSAT ≥ 15% to ≤ 45%.\n5. Stable pre-dialysis ferritin ≥ 100 to ≤ 1200 µg/L (1200 ng/mL).\n\nKey Exclusion Criteria:\n\n1. Any previous exposure to SFP.\n2. Therapy with intravenous, intramuscular or oral iron at any time between the first/screening visit and the randomization visit, or anticipated requirement for iron supplementation during the study period.\n3. Non-tunneled vascular catheter for dialysis.\n4. Scheduled for kidney transplant within the next 8 weeks.\n5. Active infection requiring systemic antimicrobial or antifungal therapy within 2 weeks prior to screening, or during screening period prior to randomization.\n6. Hospitalization within 1 month prior to screening (except for vascular access surgery).\n\nExtension Study, Open Label, Single Active Arm:\n\nKey Inclusion Criteria:\n\n1. Participated in Parent Study RMTI-SFP-6 and completed the follow-up/early term visit.\n2. Hemoglobin ≤12.0 g/dL at screening.\n3. TSAT ≤45% at screening. (Excursion of TSAT by ≤10% outside this range permitted only if all other inclusion/exclusion criteria are met).\n4. Serum ferritin ≤1000 µg/L at screening. (Excursion of ferritin by ≤10% outside this range permitted only if all other inclusion/exclusion criteria are met).\n\nKey Exclusion Criteria:\n\n1. Had a serious adverse event attributable (i.e., probably, possibly, or definitely related) to study drug or had an adverse event attributable to study drug that necessitated premature withdrawal from the double-blind, placebo-controlled crossover phase of the parent study RMTI-SFP-6.\n2. Non-tunneled vascular catheter for dialysis.\n3. Scheduled for kidney transplant within 12 weeks after entry into extension phase.\n4. Active infection requiring systemic antimicrobial or antifungal therapy within 2 weeks prior to dosing.\n5. Pregnancy or intention to become pregnant during the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment-emergent Adverse Events","description":"Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"35.1","spread":null},{"groupId":"OG002","value":"95.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Treatment-emergent Adverse Events of Intradialytic Hypotension","description":"Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met the protocol criteria for intradialytic hypotension. Intradialytic hypotension events were only to have been reported as adverse events if they exceeded the individual subject's baseline pattern of intradialytic hypotension.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"4.9","spread":null},{"groupId":"OG002","value":"12.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Related Suspected Hypersensitivity Reactions","description":"Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met protocol criteria for suspected hypersensitivity reactions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Composite Cardiovascular Events","description":"Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for composite cardiovascular events were pre-specified in the statistical analysis plan for the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"13.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hemodialysis Vascular Access Thrombotic Events","description":"Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for hemodialysis vascular access thrombotic events were pre-specified in the statistical analysis plan for the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Other Thrombotic Events","description":"Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for other thrombotic events were pre-specified in the statistical analysis plan for the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.1","spread":null},{"groupId":"OG002","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Systemic/Serious Infections","description":"Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse events of systemic/serious infections were defined in the statistical analysis plan for the study to include infections for which the subject was administered at least 3 doses of an IV antibiotic, and infections for which the subject was hospitalized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"11.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Events","description":"Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met seriousness criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"46.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Serum Iron Change From Pre-dialysis to Post-dialysis at Week 2","description":"Serum iron was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.66","spread":"5.435"},{"groupId":"OG001","value":"13.65","spread":"5.299"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.60","spread":"10.151"},{"groupId":"OG001","value":"14.97","spread":"7.753"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.91","spread":"9.243"},{"groupId":"OG001","value":"1.36","spread":"5.447"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Serum Iron Change From Pre-dialysis to Post-dialysis at Week 5","description":"Serum iron was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.97","spread":"4.731"},{"groupId":"OG001","value":"13.02","spread":"4.856"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.98","spread":"7.884"},{"groupId":"OG001","value":"37.79","spread":"11.183"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"6.834"},{"groupId":"OG001","value":"24.82","spread":"9.827"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Unsaturated Iron-binding Capacity Change From Pre-dialysis to Post-dialysis at Week 2","description":"Unsaturated iron-binding capacity was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.95","spread":"6.310"},{"groupId":"OG001","value":"28.05","spread":"7.442"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.44","spread":"6.899"},{"groupId":"OG001","value":"30.49","spread":"8.909"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.47","spread":"7.040"},{"groupId":"OG001","value":"2.49","spread":"4.910"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Unsaturated Iron-binding Capacity Change From Pre-dialysis to Post-dialysis at Week 5","description":"Unsaturated iron-binding capacity was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.80","spread":"6.745"},{"groupId":"OG001","value":"29.05","spread":"7.311"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.95","spread":"8.488"},{"groupId":"OG001","value":"12.41","spread":"8.463"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":"5.333"},{"groupId":"OG001","value":"-16.68","spread":"7.452"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Transferrin Saturation Change From Pre-dialysis to Post-dialysis at Week 2","description":"Transferrin saturation (based on TIBC derived from transferrin levels) was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 2. Because of the crossover nature of the study, the week 2 values reflect effects of SFP in the SFP/Placebo arm and effects of Placebo in the Placebo/SFP arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.31","spread":"11.357"},{"groupId":"OG001","value":"30.46","spread":"11.849"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.85","spread":"17.646"},{"groupId":"OG001","value":"30.23","spread":"14.397"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.44","spread":"17.442"},{"groupId":"OG001","value":"-0.25","spread":"10.348"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Transferrin Saturation Change From Pre-dialysis to Post-dialysis at Week 5","description":"Transferrin saturation (based on TIBC derived from transferrin levels) was assessed from samples obtained pre-dialysis and post-dialysis at a single hemodialysis during study week 5. Because of the crossover nature of the study, the week 5 values reflect effects of Placebo in the SFP/Placebo arm and effects of SFP in the Placebo/SFP arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.75","spread":"10.302"},{"groupId":"OG001","value":"28.88","spread":"10.585"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.73","spread":"15.818"},{"groupId":"OG001","value":"79.18","spread":"20.008"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"13.792"},{"groupId":"OG001","value":"50.42","spread":"18.163"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Ferritin","description":"The baseline and end of treatment predialysis ferritin levels were evaluated for the 52-week extension study to determine whether soluble ferric pyrophosphate increases iron stores.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"653.0","spread":"288.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"520.3","spread":"341.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-132.0","spread":"311.15"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Serum Iron","description":"The baseline and end of treatment predialysis serum iron levels were evaluated for the 52-week extension study to determine the effect of soluble ferric pyrophosphate on serum iron.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.650","spread":"4.6488"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.815","spread":"5.3443"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.772","spread":"5.2686"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Transferrin Saturation","description":"The baseline and end of treatment predialysis transferrin saturation were evaluated for the 52-week extension study to confirm clearance of iron derived from soluble ferric pyrophosphate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.050","spread":"10.0504"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.114","spread":"11.5075"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.835","spread":"11.7221"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence of Patients Meeting Hy's Law Criteria","description":"The peak alanine aminotransferase and the peak total bilirubin levels were evaluated per patient. Laboratory values for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Patients with alanine aminotransferase more than three times the upper limit of normal and also total bilirubin more than two times the upper limit of normal are counted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":693},"commonTop":["Procedural hypotension","Nausea","Diarrhoea","Arteriovenous fistula site complication","Haemodialysis-induced symptom"]}}}